Profile

    Group Leader

    Michael Courtney Ph.D.
    University of Turku
    miccou[at]utu.fi
    michael.courtney[at]bioscience.fi

    Contact Information

    Neuronal Signalling Laboratory
    Turku Bioscience
    University of Turku
    Biocity
    P.O. Box 123
    Tykistökatu 6A
    FIN-20521 Turku, Finland
    +358 (0)50 464 9827


    Description of the Research

    Aberrant signalling is widely accepted to play a significant role in the initiation and progression of disease. However, disease-associated signalling pathways typically play important roles in development and physiology, complicating the use of drugs targeting signalling proteins. Thus, generic mediators such as the MAP kinases contribute to development, differentiation, plasticity, survival and proliferation in addition to their well-established roles in diseases. This suggests that direct inhibition of the MAPKs themselves may be of only limited therapeutic use. Our recent work has shown that the downstream functional consequences of pathway inhibition can depend more on the frequency of inhibition than on the total integrated inhibition applied. This is an unexpected result and is likely to relate to the resonant properties of cell signalling circuits, a currently poorly understood and largely overlooked phenomenon. In order to exploit signalling pathways for the generation of novel therapeutic approaches for disorders of the nervous system and other organs, it will be necessary to only fully elucidate the mechanisms that organise these pathways into pools with pathological or physiological actions within the complex structure of cells such as neurons, but also to acquire a better understanding of cell signalling dynamics.

    Our laboratory investigates how protein interaction shape signalling dynamics in cells, with particular emphasis placed on the mechanisms that cells use to organise signalling proteins thereby ensuring specificity of function and efficiency of signal propagation. Our research combines biochemical and biophysical studies of key proteins together with cell and molecular biology approaches including protein engineering, single-cell and population-based optical measurements together with design and development of optical and other actuation approaches and techniques. This work is complemented by assay development, high-throughput methods aimed at identification of small molecules active on pathways under study. We complement these approaches by collaboration with teams focusing on preclinical models of disease, structural biology and mathematical modelling of signalling networks and circuits.

    Major Collaborations

    • Andrea Hohmann and Yvonne Lai, University of Indiana, Bloomington, USA
    • Francisco Lopez-Picón, Turku PET Centre, University of Turku
    • Florian Freudenberg, Frankfurt University Hospital, Frankfurt, Germany
    • Laura Elo, Turku Centre for Biotechnology, University of Turku
    • Jing Tang, Institute for Molecular Medicine Finland and Department of Maths and Statistics, University of Turku
    • Nael Nadif Kasri, Donders Institute for Brain, Radboud University Medical Center, Nijmegen, Netherlands
    • Tassos Papageorgiou, Turku Centre for Biotechnology, University of Turku
    • Antti Poso, University of Eastern Finland, Kuopio

    Project Funding

    NIH – NCI

    • NOS1AP as a novel target for treating pathological pain

    TEKES – Finnish Funding Agency for Innovation

    • New knowledge and business from research ideas programme

    Academy of Finland

    • Targeting schizophrenia-related phenotypes using small molecules directed against NOS1AP

    The Magnus Ehrnrooth Foundation